Get started
Author

Cécile Vissac-Sabatier

Observed names: C Vissac-Sabatier, C. Vissac-Sabatier, Cecile Vissac Sabatier, Cecile Vissac-Sabatier, Vissac-Sabatier, Cécile
Institution: UniCancer Group
ORCID: 0000-0001-5050-8302
Observed ORCID: 0000-0001-5050-8302
OpenAlex ID: A5030951678
Resveratrol increases BRCA1 and BRCA2 mRNA expression in breast tumour cell lines
2003 · P Fustier, L Le Corre, et al. · British Journal of Cancer · 50
PDF
Effects of the Phytoestrogens Genistein and Daidzein on BRCA2 Tumor Suppressor Gene Expression in Breast Cell Lines
2003 · Cecile Vissac-Sabatier, Yves-Jean Bignon, et al. · Nutrition and Cancer · 50
Differential effects of n-3 and n-6 polyunsaturated fatty acids on BRCA1 and BRCA2 gene expression in breast cell lines
2002 · Dominique J. Bernard-Gallon, Cécile Vissac-Sabatier, et al. · British Journal Of Nutrition · 47
PDF
Phytoestrogen-rich diets modulate expression of Brca1 and Brca2 tumor suppressor genes in mammary glands of female Wistar rats.
2003 · Cécile Vissac-Sabatier, Véronique Coxam, et al. · PubMed · 28
Acceptability of risk-based breast cancer screening among professionals and healthcare providers from 6 countries contributing to the MyPeBS study
2025 · Alexandra Roux, Lucile Hervouet, et al. · BMC Cancer · 11
Expression of BRCA1 and BRCA2 in male breast cancers and gynecomastias.
2003 · Dominique J Bernard-Gallon, Pierre J Déchelotte, et al. · PubMed · 11
MyPeBS International randomized study comparing personalised, risk-stratified to standard breast cancer screening in women aged 40–70: Focus on recruitment strategy in France
2022 · Marie-Eve Rouge-Bugat, Corinne Balleyguier, et al. · La Presse Médicale Open · 10
PDF
Women’s experiences of risk-stratified breast cancer screening in the MyPeBS trial: a qualitative comparative study across two European countries
2024 · Lorna McWilliams, Alexandra Roux, et al. · Psychology and Health · 7
Correction: Acceptability of risk-based breast cancer screening among professionals and healthcare providers from 6 countries contributing to the MyPeBS study
2025 · Alexandra Roux, Lucile Hervouet, et al. · BMC Cancer · 4
PDF
Differential expressions of BRCA1 and BRCA2 in infantile gynecomastia.
2004 · Dominique J Bernard-Gallon, Pierre J Dechelotte, et al. · PubMed · 4
Abstract OT2-10-02: Mypebs: An international randomized study comparing personalized, risk-stratified to standard breast cancer screening in women aged 40-70
2022 · Suzette Delaloge, Paolo Giorgi Rossi, et al. · Cancer Research · 3
Quantitative analysis of BRCA1, BRCA2 and Hmsh2 mRNA expression in colorectal Lieberkühnien adenocarcinomas and matched normal mucosa: relationship with cellular proliferation.
2005 · L Le Corre, C Vissac-Sabatier, et al. · PubMed · 3
Abstract RF7-06: Primary results of Ambre, a randomized phase 3comparing mono-chemotherapy (ct) vs abemaciclib + endocrine therapy (et) in hr+/her2- advanced breast cancer (abc) with high visceral tumor burden
2026 · V. Dieras, F. C. Bidard, et al. · Clinical Cancer Research · 2
Breast imaging readers’ performance in the PERFORMS test-set based assessment scheme within the MyPeBS international randomised study
2025 · Eleni Michalopoulou, Iain Darker, et al. · European Journal of Radiology · 1
PDF
What is the emotional impact of personalised breast cancer screening? Comparison with standard breast screening in six countries in the “My Personal Breast Screening” (MyPeBS) randomised clinical trial.
2026 · Sophie Catherine Matheson, Victoria Woof, et al.
489P PFS2 and quality of life with first-line endocrine therapy plus abemaciclib versus chemotherapy in HR+/HER2– metastatic breast cancer (MBC) with high visceral tumor burden (AMBRE trial)
2026 · G. Freyer, F.C. Bidard, et al. · ESMO Open
68P Clinical value of Circulating Tumor Cells (CTC) in the phase III randomized AMBRE trial comparing chemotherapy (CT) vs endocrine therapy (ET) and Abemaciclib in HR+HER2- advanced breast cancer (ABC)
2026 · J-Y. Pierga, S. Renault, et al. · ESMO Open
PDF
Abstract PS1-09-08: Impact of locoregional treatment after 6 months of palbociclib + letrozole combination therapy in de novo er+, her2- metastatic breast cancer patients: first results of the prospective palatine trial
2026 · C. Bonneau, P. Cottu, et al. · Clinical Cancer Research
Abstract PS3-01-12: Wisdom and mypebs: personalized breast cancer screening trials operating in distinct international contexts
2026 · K. Leggat-Barr, P. Giorgi Rossi, et al. · Clinical Cancer Research
BRCA1 and BRCA2 mRNA expression in breast cell lines is enhanced by different micronutrients.
2003 · Dominique Bernard-Gallon, Ludovic Le Corre, et al.
Effets des micronutriments sur l'expression des gènes oncosuppressifs BRCA1 et BRCA2 dans la glande mammaire
2002 · Cécile Vissac-Sabatier · OpenGrey (Institut de l'Information Scientifique et Technique)
Works count: 24
Citation count: 231
H-index: 7
I10-index: 7
Year
Topic
Type